Document:

EX-10.2

 Exhibit 10.2 
  

			
	

		 Mondelēz Global LLC

Deerfield, IL 60015 USA
  

mondelezinternational.com

 PRIVATE AND CONFIDENTIAL 

Mr. Roberto de Oliveira Marques 
 February 20, 2015

 OFFER LETTER 
 Dear Roberto, 

I am very pleased to provide you with this offer letter. It confirms the verbal offer previously extended to you for the position of Executive Vice President
and President North America for Mondelēz International, Inc. (the “Company”). This position will report to Irene Rosenfeld, Chairman and Chief Executive Officer and will be located in our North America headquarters located in East
Hanover, New Jersey. The effective date of your employment will be a mutually determined start date as soon as possible. 
 Your annualized compensation
will be as follows: 
 Annualized Compensation 

			
		
	Annual Base Salary		$875,000
		
	Annual Incentive Plan (Target- 80%*)		$700,000
		
	Target Long-Term Incentives**		$2,250,000
		
	Total Compensation		$3,825,000

  

	*	Target as a percent of base salary. 

 ** The value of the long-term incentive grants reflects the “target
grant value” of the equity grants. The actual number of shares or units will be determined pursuant to the Company’s specific valuation methodology (e.g., Black-Scholes value for stock options). 

  
 1 

 Annual Incentive Plan 

You will be eligible to participate in the Mondelēz International Management Incentive Plan (MIP), the Company’s annual incentive program. Your
target award opportunity under the MIP is equal to 80% of your base salary. The actual amount you will receive may be lower or higher depending on your individual performance and the Company’s overall performance during the year. The maximum
award under this program for 2015 is 200% of your target opportunity and the Company reserves the right to change the maximum award annually. Your MIP eligibility will begin on your hire date and, for the 2015 MIP plan year ending on
December 31, 2015, your actual award will be based on a full year at your target level and ultimately determined based on actual company and individual performance. 

Long-Term Incentives (Annual Equity Program) 
 You
will be eligible to participate in the Company’s annual equity program. Equity grants are typically made once a year, with the next annual grant made in the first quarter of 2015. For 2015, grants will be delivered with 75% of the grant value
in performance share units and 25% of the grant value in stock options (with the actual number of shares or options determined pursuant to the Company’s specific valuation methodology). Additionally, the actual target grant value is planned
based on your individual performance; provided, that, for the 2015 annual equity program, you shall receive no less than the target grant value of $2,250,000, regardless of your start date. 

All equity grants are subject to the terms and conditions of the applicable grant agreements. The annual equity program described above is based on our
current design and the Company reserves the right to change the annual equity program at any time. 
 Performance Share Units 

You will receive performance share units for the 2015-2017 performance cycle equal in value, at grant, to $1,687,500 (75% of the target total grant value). The
target number of performance share units under the 2015 – 2017 performance cycle is equal to your target grant value divided by the fair market value of Mondelēz International stock on February 18, 2015, the grant date for the 2015
annual equity grant to employees generally. 
 The actual number of shares you receive (if any) may be lower or higher depending upon the performance of
Mondelēz International, Inc. during the performance cycle based on the objectives established by the Human Resources and Compensation Committee of the Board of Directors. Shares awarded for the 2015 – 2017 performance cycle (if any) will
be delivered in early 2018 contingent on certification of the Company’s actual performance. You will also receive accumulated dividend payments at that time based on the actual number of shares vested. 

  
 2 

 We anticipate that a new three-year performance cycle will begin each January. Beginning in 2018, if you remain
employed with the Company or any of its affiliates and the Company’s performance is above threshold, shares will be awarded each year shortly after the conclusion of each performance cycle. 

Stock Options 
 The economic value of stock options to be
granted in 2015 will be approximately $562,500 (25% of the target total grant value). The number of stock options granted is typically communicated as a ratio relative to the number of full value shares (e.g., performance share units) granted based
on the “economic value” of the stock options. For 2015, Mondelēz International will grant stock options on a 5:1 ratio of stock options per full value share. This ratio may change from year to year. 

Sign On Incentives 
 As part of your employment
offer, as an incentive to join Mondelēz International, you will receive an equity sign on incentive with a grant value of $9,500,000 and a cash sign on incentive of $1,100,000 for a total sign on incentive of $10,600,000. 

The equity sign on incentive will be allocated as follows (with the actual number of restricted stock and stock options determined pursuant to the
Company’s specific valuation methodology): 
  

	 	•	 	$4,750,000 in restricted stock that will vest 30%, 30% and 40% annually over the first three anniversaries of your date of hire and, except as otherwise set forth below, subject to the other terms and conditions in the
Mondelēz International’s standard Restricted Stock Agreement, inclusive of the standard provisions in case of death or disability. 

  

	 	•	 	$4,750,000 in stock options that will vest 30%, 30% and 40% annually over the first three anniversaries of your date of hire and, except as otherwise set forth below, subject to the other terms and conditions in the
Mondelēz International’s standard Non-Qualified U.S. Stock Option Agreement, inclusive of the standard provisions in case of death or disability. 

In addition, upon an involuntary termination without Cause (as defined below) at any time during the vesting period, you shall (i) continue to vest in
unvested restricted stock on the original vesting dates and (ii) immediately vest in all outstanding stock options with a one-year post-termination exercise period. For the avoidance of doubt, the immediately preceding sentence shall only apply
to restricted stock and stock options received in conjunction with the equity sign on incentive. 
 The cash sign on incentive will be payable in a lump-sum
within 60 days of your hire date subject to a full repayment upon any termination of employment within the first two (2) years of your hiring other than an involuntary termination of employment without Cause (as defined below) or separation due
to death or disability. 

  
 3 

 For purposes of this offer letter, Cause means: 1) continued failure to substantially perform the job’s
duties (other than resulting from incapacity due to disability); 2) gross negligence, dishonesty, or violation of any reasonable rule or regulation of the Company where the violation results in significant damage to the Company; or 3) engaging in
other conduct which materially adversely reflects on the Company in any material respect. 
 Executive Deferred Compensation Plan 

You will be eligible to participate in the Executive Deferred Compensation Plan. This program allows you to voluntarily defer a portion of your salary and/or
your annual incentive awarded to a future date. Additional information for this program can be made available upon request. 
 Change in Control Plan

 You will be a participant in the Mondelēz International, Inc. Change in Control Plan for Key Executives (“CIC Plan”). The CIC Plan
provides certain benefits upon an involuntary termination without cause or voluntary termination for good reason following a change in control. A copy of the CIC Plan will be provided upon request. 

Stock Ownership Guidelines 
 You will be required
to attain and hold Company stock equal in value to four times your annual base salary at the time of hire. Under current guidelines, you will have five years from your date of employment to achieve this level of ownership. Stock held for ownership
determination includes common stock held directly or indirectly, unvested restricted stock or share equivalents held in the Company’s 401(k) plan. It does not include stock options or unvested performance share units. The Company reserves the
right to change the guidelines at any time. 
 You will also be required to hold the “net” shares on your annual grants received upon vesting, in
the case of restricted stock or performance share units, or exercise, in the case of stock options, for a period of at least one year from the respective vesting or exercise dates. Net shares are the number of shares resulting from the vesting of
restricted stock or performance share units or the exercise of stock options reduced by the number of shares required to satisfy any applicable tax withholding or costs associated with the respective vesting or exercise. 

Other Benefits 
 If your employment with the
Company ends due to an involuntary termination other than for Cause (as defined above), you will receive severance arrangements no less favorable than those accorded recently terminated senior executives of the Company. The amount of any severance
pay under such arrangements shall be paid in equal installments at the regularly scheduled dates for payment of salary to Company executives and beginning within 30 days of your termination (subject to any applicable delay under Code
section 409A as described below). 

  
 4 

 Additionally, under the current policies in place, you will be eligible for the Company’s discretionary
financial planning program, which reimburses eligible employees up to $7,500 per year for eligible financial planning expenses, and car allowance program, which provides a car allowance of up to $15,000 per year. The annual car allowance can be used
for any purpose including purchase of a car, commuting expenses etc. 
 Your offer also includes Mondelēz Global LLC’s comprehensive benefits
package available to full-time salaried U.S. employees and you will be eligible for 30 days of paid time off. Details and terms of these comprehensive benefits will be provided separately. 

Restrictive Covenants 
 As a condition to this
offer of employment and corresponding consideration, you agree to the terms and conditions of the Confidential Information, Intellectual Property and Restrictive Covenants Agreement (the “Agreement”) attached hereto as Appendix
A and will acknowledge such Agreement by signing the Agreement simultaneously with this offer of employment. 
 Section 409A of the
Internal Revenue Code of 1986, as amended (the “Code”) 
 If you are subject to US tax law and if you are a “specified employee”
(within the meaning of Code section 409A) as of your separation from service (within the meaning of Code section 409A): (a) payment of any amounts under this offer letter (or under any severance arrangement pursuant to this offer letter) which
the Company determines constitute the payment of nonqualified deferred compensation (within the meaning of Code section 409A) and which would otherwise be paid upon your separation from service shall not be paid before the date that is six months
after the date of your separation from service and any amounts that cannot be paid by reason of this limitation shall be accumulated and paid on the earlier of (x) your death and (y) the first day of the seventh month (or as soon as
administratively possible thereafter) following the date of your separation from service (within the meaning of Code section 409A); and (b) any welfare or other benefits (including under a severance arrangement) which the Company determines
constitute the payment of nonqualified deferred compensation (within the meaning of Code section 409A) and which would otherwise be provided upon your separation from service shall be provided at your sole cost during the first six-month period
after your separation from service and, on the first day of the seventh month following your separation from service (or as soon as administratively possible), the Company shall reimburse you for the portion of such costs that would have been
payable by the Company for that period if you were not a specified employee. 

  
 5 

 Payment of any reimbursement amounts and the provision of benefits by the Company pursuant to this offer letter
(including any reimbursements or benefits to be provided pursuant to a severance arrangement) which the Company determines constitute nonqualified deferred compensation (within the meaning of Code section 409A) shall be subject to the following:

  

	(a)	the amount of the expenses eligible for reimbursement or the in-kind benefits provided during any calendar year shall not affect the amount of the expenses eligible for reimbursement or the in-kind benefits to be
provided in any other calendar year; 

  

	(b)	the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the calendar year in which the expense was incurred; and 

 

	(c)	your right to reimbursement or in-kind benefits is not subject to liquidation or exchange for any other benefit. 

The parties hereto intend that all compensation, benefits and other payments made to you hereunder will be provided or paid to you in compliance with all
applicable provisions, or an exemption or exception from the applicable provisions of Code section 409A and the regulations and rulings issued thereunder, and the rulings, notices and other guidance issued by the Internal Revenue Service
interpreting the same, and this offer letter shall be construed and administered in accordance with such intent. The parties also agree that this offer letter may be modified, as reasonably agreed by the parties, to the extent necessary to comply
with all applicable requirements of, and to avoid the imposition of additional tax, interest and penalties under Code section 409A in connection with the compensation, benefits and other payments to be provided or paid to you hereunder. Any such
modification shall maintain the original intent and benefit to the Company and you of the applicable provision of this offer letter, to the maximum extent possible without violating Code section 409A. 

Other Terms and Conditions 
 You will be a U.S.
employee of Mondelēz Global LLC and your employment status will be governed by and shall be construed in accordance with the laws of the United States. As such, your status will be that of an “at will” employee. This means that either
you or Mondelēz International is free to terminate the employment relationship at that time, for any reason. 
 As an officer of the Company, you will
be indemnified against various criminal or civil actions in accordance with the Company’s amended and restated Articles of Incorporation in a manner no less favorable than that provided for other senior executives of the Company. Furthermore,
you will be covered under the Company’s applicable Directors and Officers liability insurance policy in a manner no less favorable than that provided for other senior executives of the Company. 

  
 6 

 Additionally, this offer is contingent upon: 

 

	 	(i)	successful completion of our pre-employment checks, which may include a background screen, reference check and post-offer drug test pursuant to testing procedures determined by Mondelēz International; and

  

	 	(ii)	the necessary approval of the Company’s Board of Directors and Human Resources and Compensation Committee. 

Should you have any questions concerning this information, please call me. 
  

					
	 /s/ Karen May
  
	 		 	      February 27, 2015
	Karen May	 		 	Date
	Executive Vice President, Human Resources	 		 	

 I have read the above terms and conditions and, by signing below, do accept this offer and acknowledge that I understand that
this offer is contingent upon successful completion of the Company’s pre-employment checks and the necessary approvals by the Company’s Board of Directors and Human Resources and Compensation Committee. This letter does not, in any way,
constitute an express or implied contract for employment. 
  

					
	 /s/ Roberto de Oliveira Marques

 
	 		 	        February 27, 2015
	Roberto de Oliveira Marques	 		 	Date

 [Signature Page to Roberto de Oliveira Marques Offer Letter] 

  
 7 

 APPENDIX A 

CONFIDENTIAL INFORMATION, INTELLECTUAL PROPERTY 

AND RESTRICTIVE COVENANTS AGREEMENT 

This Confidential Information, Intellectual Property and Restrictive Covenants Agreement (“Agreement”) is made between the person
specified in that certain offer of employment (“Executive”) and Mondelēz Global LLC (and any currently or previously-affiliated companies, parent companies, successors or predecessors, including Mondelēz International, Inc.,
Kraft Foods Inc., Kraft Foods Group, Inc., and Kraft Foods Global, Inc., hereafter, collectively, “MG”). 
 WHEREAS, this
Agreement is an extension of and incorporated into the offer of employment between Executive and MG under which MG desires and agrees to employ Executive and Executive desires and agrees to be employed by MG (the “Offer Letter”); and 

WHEREAS, as part of performing Executive’s responsibilities for MG, Executive will have access to MG’s Confidential
Information (as defined in Paragraph 2(a) below) and Intellectual Property (as defined in Paragraph 3(a) below). 
 NOW, THEREFORE,
for good and valuable consideration, including the promises and covenants contained in this Agreement, including monetary consideration, Executive’s employment with MG and Executive’s access to and use of MG’s Confidential Information
and Intellectual Property, MG and Executive hereby agree as follows: 
 1. Consideration. In addition to Executive’s
employment with MG and Executive’s access to and use of MG’s Confidential Information, as consideration for this Agreement, MG will provide Executive with such consideration described in the Offer Letter, including, but not limited to, any
sign on incentives and participation in the annual incentive plan and equity program. 
 2. Confidential Information.  

(a) Executive recognizes that MG derives economic value from information and trade secrets created (whether by Executive or
others) and used in MG’s business which is not generally known by the public, including but not limited to certain sales, marketing, strategy, financial, product, personnel, manufacturing, technical and other proprietary information and
material (“Confidential Information”) which are the property of MG. Executive understands that this list is not exhaustive, and that Confidential Information also includes other information that is marked or otherwise identified as
confidential or proprietary, or that would otherwise appear to a reasonable person to be confidential or proprietary in the context and circumstances in which the information is known or used. Executive expressly acknowledges and agrees that, by
virtue of Executive’s employment with MG, Executive will have access to and will use certain Confidential Information and that such Confidential Information constitutes MG’s trade secrets and confidential and proprietary business
information, all of which is MG’s exclusive property. For purposes of this Agreement, Confidential Information does not include information that is or may become known to Executive or to the public from sources outside MG and through means
other than a breach of this Agreement or disclosed by Executive after written approval from MG. 

  
 1 

 (b) Executive further understands and acknowledges that this Confidential
Information and MG’s ability to reserve it for the exclusive knowledge and use of MG is of great competitive importance and commercial value to MG. Executive agrees that Executive will treat all Confidential Information as strictly confidential
and Executive will not, and will not permit any other person or entity to, directly or indirectly, without the prior written consent of MG: (i) use Confidential Information for the benefit of any person or entity other than MG;
(ii) remove, copy, duplicate or otherwise reproduce any document or tangible item embodying or pertaining to any of the Confidential Information, except as required to perform Executive’s responsibilities for MG; and (iii) while
employed and thereafter, publish, release, disclose, deliver or otherwise make available to any third party any Confidential Information by any communication, including oral, documentary, electronic or magnetic information transmittal device or
media. Notwithstanding the foregoing, Executive shall be permitted to disclose, after (to the extent legally permissible) first providing reasonable written notice to MG’s Legal Department which allows MG the time and opportunity to object,
Confidential Information to the extent (x) required by law, subpoena, or applicable government or regulatory authority or (y) appropriate in connection with a legal dispute. 

(c) Executive agrees and understands that the obligations under this Agreement with regard to the non-disclosure and non-use of particular Confidential Information shall commence immediately upon Executive first having access to Confidential Information (whether before or
after Executive begins employment with MG) and shall continue to exist during and after Executive’s employment with MG for so long as such information remains Confidential Information and is not public knowledge other than as a result of the
Executive’s breach of this Agreement or breach by those acting in concert with Executive or on Executive’s behalf. 

(d) Executive understands that improper use or disclosure of the Confidential Information by Executive will cause MG to incur
financial costs, loss of business advantage, liability under confidentiality agreements with third parties, civil damages and criminal penalties. 

3. Intellectual Property. 

(a) Disclosure and Assignment. Executive agrees to make prompt written disclosure to MG, to hold in trust for the sole
right and benefit of MG, and to assign to MG all Executive’s right, title and interest in and to any patents, trademarks, copyrights, ideas, inventions (whether not patented or patentable), original works of authorship (published or not),
developments, improvements or trade secrets which Executive may solely or jointly conceive or reduce to practice, or cause to be conceived or reduced to practice, during the period of Executive’s employment with MG and relating in any way to
the business or contemplated business, 

  
 2 

 
research or development of MG (regardless of when or where the Intellectual Property is prepared or whose equipment or other resources is used in preparing the same) (collectively
“Intellectual Property”). Executive recognizes, provided prompt and full disclosure by Executive to MG, that this Agreement will not be deemed to require assignment of any invention which was developed entirely on Executive’s own time
without using MG’s equipment, supplies, facilities or trade secrets and neither relates to MG’s actual or anticipated business, research or development, nor resulted from work performed by Executive (solely or jointly with others) for MG.

 (b) Original Works. Executive acknowledges that all original works of authorship which have been or are made by
Executive (solely or jointly with others) within the scope of Executive’s employment with MG and which are protectable by copyright are the property of MG. To the extent that any such original works have not already been transferred to or owned
by MG, Executive hereby assigns all of Executive’s right, title and interest in those works to MG. 
 (c)
Cooperation. Executive agrees to assist MG in every reasonable and proper way to obtain and enforce United States and foreign proprietary rights relating to any and all patents, trademarks, inventions, original works of authorship,
developments, improvements or trade secrets of MG in any and all countries. Executive will execute, verify and deliver (i) such documents and perform such other acts (including appearing as a witness) as MG may reasonably request for use in
applying for, obtaining, perfecting, evidencing, sustaining and enforcing such proprietary rights and the assignment thereof, and (ii) assignments of such proprietary rights to MG or its designee. Executive’s obligation to assist MG with
respect to proprietary rights in any and all countries shall continue beyond the termination of employment. 
 (d) Other
Obligations. In addition to Executive’s other obligations under this Paragraph 3, Executive shall promptly disclose to MG fully and in writing all patent applications filed by Executive or on Executive’s behalf. At the time of
each such disclosure, Executive shall advise MG in writing of any inventions that Executive believes are not required to be assigned pursuant to this Paragraph. Executive shall at that time provide to MG in writing all evidence necessary to
substantiate that belief. Executive understands that MG will keep in confidence, will not disclose to third parties and will not use for any unauthorized purpose without Executive’s consent, any proprietary information disclosed in writing to
MG pursuant to this Agreement relating to inventions that are not required to be assigned pursuant to this subparagraph 3(d) and which were created or developed by Executive after termination of Executive’s employment. Executive will
preserve the confidentiality of any such invention that is or may be required to be assigned, in whole or in part, pursuant to this Paragraph 3. Executive agrees to keep and maintain adequate and current records (in the form of notes, sketches,
drawings and in any other form that may be required by MG) of all proprietary information developed by Executive and all inventions made by Executive during the period of employment at MG, which records shall be available to and remain the sole
property of MG at all times. 

  
 3 

 4. Restrictive Covenants. Executive understands and agrees that the nature of
Executive’s position with MG provides Executive with access to and knowledge of MG’s Confidential Information and places Executive in a position of trust and confidence with MG. Because of MG’s legitimate business interests and for
the consideration afforded in this Agreement and Offer Letter, Executive agrees that during Executive’s employment with MG and for a period of twelve (12) months following the termination of Executive’s employment from MG for any
reason (the “Restricted Period”), Executive shall not engage in the following Prohibited Conduct: 
 (a) Non-Competition.
Executive agrees that during the Restricted Period and in any geographic area in which Executive directly or indirectly performed responsibilities for MG or where Executive’s knowledge of Confidential Information would be useful to a competitor
in competing against MG, Executive will not engage in any conduct in which Executive contributes Executive’s knowledge and skills, directly or indirectly, in whole or in part, as an executive, employee, employer, owner, operator, manager,
advisor, consultant, agent, partner, director, stockholder, officer, volunteer, intern or any other similar capacity to a competitor or to an entity engaged in the same or similar business as MG, including those engaged in the business of
production, sale or marketing of snack foods (including, but not limited to gum, chocolate, confectionary products, biscuits or any other product or service Executive had reason to know was under development by MG during Executive’s employment
with MG) without the written consent of MG’s Executive Vice President of Global Human Resources, or designee, such consent to be provided by MG in its sole and absolute discretion. Under no circumstances may Executive engage in any activity
that may require or inevitably require Executive’s use or disclosure of MG’s Confidential Information. 
 (b) Non-Solicitation
of Customers or Accounts. Executive understands and acknowledges that MG has expended and continues to expend significant time and expense in pursuing and retaining its customers and accounts, and that the loss of customers and accounts would
cause significant and irreparable harm to MG. Executive therefore agrees that during the Restricted Period and for Executive or the direct or indirect benefit of any entity engaged in the same or similar business as MG, including those engaged in
the business of production, sale or marketing of snack foods (including but not limited to gum, chocolate, confectionary products, biscuits or any other product or service Executive had reason to know was under development by MG during
Executive’s employment with MG), Executive will not (i) solicit business from or perform services for, or for the benefit of, any customer or account of MG with which Employee had contact, participated in the contact, or about which
Executive had knowledge of Confidential Information by reason of Executive’s relationship with MG within the twelve (12) month period prior to Executive’s separation of employment from MG, or (ii) solicit business from or perform
services for, or for the benefit of, any customer or account MG actively pursued for business and with which Executive had contact, participated in the contact, or about which Executive had knowledge of Confidential Information by reason of
Executive’s relationship with MG within the twelve (12) month period prior to Executive’s separation of employment from MG. 

  
 4 

 (c) Non-Solicitation of Employees. Executive understands and acknowledges that MG has
expended and continues to expend significant time and expense in recruiting and training its employees, and that the loss of employees would cause significant and irreparable harm to MG. Executive therefore agrees and covenants that during the
Restricted Period Executive will not directly or indirectly solicit, hire, recruit, attempt to hire or recruit, or induce the termination of employment of any executive of MG. 

5. Return of MG Property. Unless otherwise specified by MG in a separation or other similar-type agreement, within five
(5) days of Executive’s separation of employment from MG or as such other time as specified in the sole discretion of MG, Executive shall return all Confidential Information and all other MG property (whether in electronic or paper form)
in Executive’s possession, including documents, files, manuals, handbooks, notes, keys and any other items, files or documents (whether in electronic or paper form). 

6. This Agreement to Be Kept Confidential. Executive understands that this Agreement is unique to Executive and Executive agrees
it is confidential and that Executive will not disclose this Agreement or its terms to anyone other than (a) a third party consistent with Paragraph 9 of this Agreement, (b) Executive’s legal or tax advisor, (c) Executive’s
immediate family, (d) in a legal action to enforce the terms of this Agreement, (e) the EEOC or similar state or local agency in connection with the filing or investigation of a charge, or (f) as required by law. Executive further
agrees that if Executive discloses the existence of terms of this Agreement to anyone under (a) or (f) above, Executive will inform them of the confidentiality requirements of this Paragraph 6 and require that they agree to be bound
by such requirements 
 7. No Disparagement or Harm. Executive agrees that, in discussing Executive’s relationship with
MG and its affiliated and parent companies and their business and affairs, Executive will not disparage, discredit or otherwise treat in a detrimental manner MG, its affiliated and parent companies or their officers, directors and Executives. This
Paragraph does not, in any way, restrict or impede Executive from exercising protected rights including the right to communicate with any federal, state or local agency, including any with which a charge has been filed, to the extent that such
rights cannot be waived by agreement or from complying with any applicable law or regulation or a valid order of a court of competent jurisdiction or an authorized government agency, provided that such compliance does not exceed that required by the
law, regulation or order. Executive shall promptly provide written notice of any such order to MG’s legal department. 
 8.
Remedies. Should Executive breach any of the provisions contained in Paragraph 4 or commit a material breach of any of the provisions contained in Paragraphs 2, 3, 5, and/or 7 of this Agreement, in addition to any other remedies
available to MG, Executive will be obligated to pay back to MG any cash payment(s) received pursuant to this Agreement (other than base salary and annual incentive previously paid to Executive) following the exhaustion of all legal remedies by both
Executive and MG. MG and Executive further acknowledge and agree that MG will or would suffer irreparable injury in the event of a breach or violation or threatened breach or violation of the provisions set forth in this Agreement, and agree that in
the event of a breach or violation of such 

  
 5 

 provisions MG will be awarded injunctive relief by a court of competent jurisdiction to prohibit any such
violation or breach, and that such right to injunctive relief will be in addition to any other remedy which may be ordered by the court or an arbitrator. The equitable relief shall be in addition to, not in lieu of, legal remedies, monetary damages
or other available forms of relief. 
 9. Notification. Executive agrees that in the event Executive is offered to enter into
an employment relationship with a third party at any time during the Restricted Period, Executive shall immediately advise said other third party of the existence of this Agreement and shall immediately provide said person or entity with a copy of
this Agreement. 
 10. Arbitration of Claims. In the event either Executive or MG contests the interpretation or application
of any of the terms of this Agreement, the complaining party shall notify the other in writing of the provision that is being contested. If the parties cannot satisfactorily resolve the dispute within thirty (30) days, the matter will be
submitted to arbitration. An arbitrator will be chosen pursuant to the American Arbitration Association’s (“AAA”) Employment Arbitration Rules and Mediation Procedures. The arbitrator’s fees and expenses and filing fees shall be
borne equally by Executive and MG. The hearing shall be held at a mutually agreeable location and the arbitrator shall issue a written award which shall be final and binding upon the parties. Executive agrees to waive the right to a jury trial.
Notwithstanding anything contained in this Paragraph 10, MG shall each have the right to institute judicial proceedings against Executive or anyone acting by, through or under Executive, in order to enforce its rights under Paragraphs 2 through 7
through specific performance, injunction, or similar equitable relief. Claims not covered by arbitration are those claims seeking injunctive and other relief due to unfair competition, due to the use or unauthorized disclosure of trade
secrets or confidential information, due to wrongful conversion, breach of the Intellectual Property covenants, and the breach of the restrictive covenants set forth in paragraphs 2 through 7. 

11. Entire Agreement and Severability. This is the entire agreement between Executive and MG on the subject matter of this
Agreement. This Agreement may not be modified or canceled in any manner except by a writing signed by both Executive and an authorized MG official. Executive acknowledges that MG has made no representations or promises to Executive, other than those
in this Agreement. If any provision in this Agreement is found to be unenforceable, all other provisions will remain fully enforceable. The covenants set forth in this Agreement shall be considered and construed as separate and independent
covenants. Should any part or provision of any provision of this Agreement be held invalid, void or unenforceable in any court of competent jurisdiction, such invalidity, voidness or unenforceability shall not render invalid, void or unenforceable
any other part or provision of this Agreement. If the release and waiver of claims provisions of this Agreement are held to be unenforceable, the parties agree to enter into a release and waiver agreement that is enforceable. 

12. Not a Contract of Employment. Executive acknowledges and understands that nothing in this Agreement is intended to, nor
should be construed to, alter the at-will nature of Executive’s employment relationship with MG, nor to guarantee Executive’s employment for any specified term. Notwithstanding any provision of this Agreement, Executive and/or MG may
terminate Executive’s employment at-will, for any reason permitted by law, with or without notice, and upon such termination, the rights and obligations set forth herein shall continue as expressly provided. 

  
 6 

 13. Tolling. Should Executive violate any of the terms of the confidentiality or
restrictive covenant obligations in this Agreement, the obligation at issue will run from the first date on which Executive ceases to be in violation of such obligation. 

14. Governing Law. This Agreement shall be governed under and construed in accordance with the laws of the State of New Jersey
without giving effect to any choice of law or conflict of law provision or rule that would cause the application of the laws of any jurisdiction other than New Jersey. Executive agrees that any legal proceeding concerning this Agreement may only be
brought and held in a state or federal court located in the State of New Jersey. Executive consents to the personal jurisdiction of such courts and agrees not to claim that any such courts are inconvenient or otherwise inappropriate. 

15. Successors and Assigns. This Agreement shall be binding upon, and inure to the benefit of, the parties and their respective
successors and permitted assigns. Executive may not assign Executive’s rights and obligations under this Agreement without prior written consent of MG. MG may assign this Agreement and/or its rights or obligations under this Agreement. Any and
all rights and remedies of MG under this Agreement shall inure to the benefit of and be enforceable by any successor or assignee of MG. 

  
 7 

 IN WITNESS WHEREOF, the Executive understands and agrees this Agreement is an extension of
and incorporated into the offer of employment between Executive and MG and has executed this Agreement freely and voluntarily with the intention of being legally bound by it. 

EXECUTIVE 

			
		
	By:		 /s/ Roberto de Oliveira
Marques

			
		
	Print Name:		Roberto de Oliveira Marques

			
		
	Dated:		February 27, 2015

  

	
	
	
	

 [Signature Page to Confidential Information, Intellectual Property and Restrictive Covenants Agreement]

  
 8Exhibit 10.19

 

A request for confidential treatment has been made with respect to portions of the following document that are marked with [*]. The redacted portions have been filed separately with the SEC.

 

First Amendment to Development and Manufacturing Services Agreement

 

This first amendment to the DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT (hereinafter referred to as the “First Amendment”) is entered into between the QuaDPharma, LLC, a Delaware Limited Liability Company (“QuaDPharma”); and Anterios, Inc., a Delaware corporation, with offices located at 60 East 42nd St, New York, New York 10165 (“Anterios”); and is made as of April 23, 2015.

 

Background

 

Anterios and QuaDPharma are parties to a DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT that was effective August 17, 2011 (the “Services Agreement”).

 

Anterios and QuaDPharma desire to amend the Services Agreement to extend the agreement.

 

Therefore, Anterios and QuaDPharma hereby agree as follows:

 

I              Paragraph 14.1 of the Services Agreement, “Term,” is replaced in its entirety with the following:

 

Term. This Agreement will take effect as of the Effective Date and, unless earlier terminated pursuant to this Section 14, will expire on the later of (a) [*], or (b) the completion of Services under the last Work Order executed by the parties prior to the [*] anniversary of the Effective Date. The term of this Agreement may be extended continuously for additional [*] year periods upon mutual written agreement at least [*] prior to the expiration of the then current term.

 

IN WITNESS WHEREOF, the parties hereto have duly executed this First Amendment effective as of the date first above written.

 

 

	
QUADPHARMA, LLC
    	
ANTERIOS, INC.
    
	
 
    	
 
    
	
By:
    	
/s/ Stephen A. Panaro, Ph.D.
    	
 
    	
By:
    	
/s/ Jon Edelson, MD
    
	
Name:
    	
Stephen A. Panar, Ph.D
    	
 
    	
Name:
    	
Jon Edelson, MD
    
	
Title:
    	
President & COO
    	
 
    	
Title:
    	
CEO & President
    

 

	
Date:
    	
04/24/2015
    	
 
    	
Date:
    	
4/25/2015

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}]]